checkmate 274: biomarkers linked to disease-free survival with adjuvant nivolumab
Published 2 years ago • 91 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
1:35
checkmate 274: adjuvant nivolumab versus placebo for urothelial carcinoma
-
4:22
checkmate 274 & ev-301: highlights in uc from asco gu
-
2:06
checkmate 274: nivolumab versus placebo in high-risk urothelial cancer
-
2:13
adjuvant nivolumab as soc for high-risk muscle-invasive urothelial carcinoma after radical resection
-
12:12
checkmate 274 adjuvant nivolumab in urothelial cancer | an oncologist's take
-
3:12
nivolumab for perioperative esophageal and gastroesophageal cancer: checkmate 577
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
2:53
matthew galsky, md, elaborates on outcomes from the checkmate 274 trial
-
5:44
4-year results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma
-
2:36
matthew galsky, md, on the checkmate-274 study in high risk, muscle-invasive urothelial carcinoma
-
5:18
checkmate577: nivolumab in ec/gejc
-
31:19
new and emerging therapeutic strategies in bladder cancer
-
2:01
elucidating biomarkers of response in the relativity-047 trial
-
6:31
checkmate 649 biomarker analyses of nivo ipi vs chemo for patients with gc/gejc/eac
-
4:14
adjuvant nivolumab in patients with resected esophageal or gej cancer (checkmate 577)
-
7:31
the pivot-02 trial: nktr-214 with nivolumab
-
8:16
nivolumab for oesophageal cancer following chemoradiation therapy
-
4:47
nivolumab chemotherapy combination treatment: checkmate649 and attraction-4
-
1:42
dr. mcdermott on immotion150 trial in rcc